have suggested that by using a dual-targeting exosome-loaded drug, cGAMP (cGAMP@dual-anti-Exos), whose surface is modified with two antibodies (anti-PD-L1 and anti-CD40), two-step activation of DCs and blocking of cancer cell PD-L1, the survival rate of mice inoculated with the drug is up to 60%. The gene discussed is CD274; the disease is cancer.